Eighth Patent allowed for NuOncology Labs, Inc For Cancer Treatment Compounds.Business Editors/Health & Medical Writers VIRGINIA BEACH Virginia Beach, resort city (1990 pop. 393,069), independent and in no county, SE Va., on the Atlantic coast; inc. 1906. In 1963, Princess Anne co. and the former small town of Virginia Beach were merged, giving the present city an area of 302 sq mi (782 sq km). , Va.--(BW HealthWire)--June 21, 2002 NuOncology Labs, Inc, (Nulabs) announced today it has received a Notice of Allowance from the US Patent and Trademark office for claims relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc novel compounds and Pharmaceutical compounds that may be effective for the treatment of a variety of human cancers. This will be the fourth (4) patent issued to Nulabs' subsidiary, International Phytochemistry phytochemistry, n the scientific study and classification of the chemical constituents of plants. Research Laboratory, LTD LTD 1 Laron-type dwarfism 2 Leukotriene D 3 Long-term depression, see there 4. Long-term disability (IPRLL). Four (4) other patents have been issued to Paracure, Inc, another Nulabs' subsidiary. Mr. Richard J. Marcel Marcel the fast ebbing of time impels him to devote his life to recording it. [Fr. Lit.: Proust Remembrance of Things Past] See : Time , CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , NuOncology Labs, Inc, stated " When the patent is issued this will be a significant addition to our intellectual property portfolio and will further support and protect the work and intellectual property of our Kazakstan partners and NuOncology share holders. Further more, we now believe that our patent position is strong enough to initiate the clinical development of Arglabin in the USA." Note: Statements in this document that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including risks relating to the early state of products under development; uncertainties relating to clinical trials; dependence on third parties; further capital needs; and risks relating to the commercialization, if any, of the Companies proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks) |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion